The Latest Breaking News from Recursion Pharmaceuticals

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

The drug developer's latest capital raise, a $150 million private placement, comes during a difficult market environment.

 

The drug developer aims to build novel maps of biology. What the heck does that mean, exactly?